- Leclerc hails Ferrari fightback from torrid Singapore GP qualifying
- Belgian Evenepoel retains world title in 'toughest time trial'
- Sosa rescues point for Forest against Brighton
- Last-gasp Boniface gives Leverkusen victory over Wolfsburg in seven-goal thriller
- Swiss voters reject environment, pensions reforms: official results
- No fairytale ending for Ricciardo after 13 years in Formula One
- Israel and Hezbollah urged to step back from the brink
- What is the UN's 'Pact for the Future'?
- Norris dominates Singapore Grand Prix to cut Verstappen's title lead
- From bullets to ballots: Sri Lanka's comrade president-elect
- McLaren's Lando Norris wins Singapore GP to narrow F1 title race
- UN adopts pact promising to build 'brighter future' for humanity
- Military escalation not in Israel's 'best interest': White House
- Marxist leader declared Sri Lanka's president-elect
- Classes resume at Bangladesh university at heart of protests
- 'Barely anyone left': Sudan's El-Fasher devastated by fighting
- 'Warrior' Joshua vows to fight on despite Dubois mauling
- Martin extends MotoGP lead as Bastianini wins at Misano and Bagnaia crashes out
- New French government instantly under pressure on multiple fronts
- Australia's Brown adds world title to Olympic time trial gold
- Russian strike on Ukraine's Kharkiv wounds 21
- UK's Starmer rules out austerity as Labour conference opens
- Swiss voters reject environment, pensions reforms: projected results
- Israel says 'landed blows' on Hezbollah as Lebanon violence intensifies
- Roma CEO steps down amid anger over club icon De Rossi's sacking
- Incoming French government under pressure on multiple fronts
- Hezbollah rockets strike near Israel's Haifa as UN warns of 'catastrophe'
- Haddad Maia roars back to beat Kasatkina in Korea Open final
- All-rounder Ashwin powers India to 280-run Test win over Bangladesh
- Failed Springbok 'gamble' sets up rugby championship decider
- Lebanon strikes send Israelis to shelters as UN warns of 'catastrophe'
- Far-right AfD eyes new win in east German state vote
- Tony Popovic set to become new Socceroos coach - reports
- All-round Ashwin powers India to big Test win over Bangladesh
- NZ chase 275 to win first Sri Lanka Test after Patel bags six
- Ashwin bags six wickets as India hammer Bangladesh in first Test
- Nascent French government under pressure on multiple fronts
- Angry French cognac makers see red over Chinese tariffs threat
- Protect the prosciutto: Italy battles swine fever
- UN holds 'Summit of the Future' to tackle global crises
- Marxist leader set to become Sri Lanka's next president
- From blades to pull-up bars: UK charity tackles knife crime
- Swiss vote on pensions and environment protections
- No pain, no gain: Chinese pro wrestlers fight for recognition
- UAE leader seeks to deepen 'strategic' ties in US visit during Mideast crisis
- Hezbollah takes heavy hits but still fighting Israel
- Floods, landslides hit central Japan months after major quake
- All Blacks coach Robertson demands better finishing
- Argentina edge South Africa to keep title hopes alive
- Biden says China 'testing us,' in hot mic remarks to Quad allies
Novo Nordisk spends big in France to expand obesity drug capacity
Danish pharmaceutical giant Novo Nordisk will announce Thursday a major investment in a French production site to expand capacity for a blockbuster anti-obesity drug, the French presidency said.
In a deal to be sealed officially with President Emmanuel Macron, Novo Nordisk will invest 2.1 billion euros ($2.3 billion) in an existing facility in Chartres, southwest of Paris.
Novo Nordisk is the European Union's most valuable company with market capitalisation of around $460 billion, mostly thanks to growing use of its anti-diabetes drugs as weight-loss derivatives.
The Danish company has found that its Semaglutide medication, originally meant for diabetes, is also effective against obesity, giving it massive global potential.
Marketed as Wegovy in the United States, Denmark, Norway and Germany, the drug helps chronically overweight patients by stimulating insulin secretion and acting as an appetite suppressant.
Goldman Sachs, a financial firm, predicted last month that the global market for anti-obesity medication (AOM) could grow to $100 billion by 2030, against around six billion now.
Obesity rates have almost tripled around the world since 1975, and are set to rise further, it said.
In the United States alone, 15 million adults were likely to receive anti-obesity treatment by 2030, Goldman said, identifying Novo Nordisk, and rivals Eli Lilly, as the world's two dominant AOM makers by then.
Novo Nordisk will double the size of its French site, adding 500 jobs to the 1,600 already there. The investments mostly concern the production of diabetes drugs, cartridges and vials, it said, with a 2028 target date for completion.
Novo Nordisk already said this month it was investing 42 billion Danish kroner ($6.1 billion) to expand its facilities in Denmark.
The French presidency credited Macron's drive to attract foreign industrial investment to France for the Novo deal.
It follows a 6.7-billion-euro ($7.3 billion) pledge for the production and recycling of electric batteries by Asian firms.
An investment of 500 million euros by US pharma company Pfizer was announced in May during a "Choose France" investment conference hosted by Macron.
Stung by recent drugs shortages in France, including for basic antibiotics and pain medicine paracetamol, the government has been keen to bring pharmaceutical production back to the country.
Novo Nordisk said it hopes to win full regulatory approval to sell Wegovy as an anti-obesity drug in France next year.
Y.Aukaiv--AMWN